$15.71-1.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Just reported
From Personalis, Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Actual
$25.6M
+77% y/y
+14% q/q
Guided
—
No guide given
Actual
-$0.32
Guided
—
No guide given
Actual
-$35.5M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $25.6M | $14.5M | +76.59% |
| Profit | -$33.8M | -$21.7M | -56.11% |
| Profit per share | -$0.32 | -$0.24 | -33.33% |
| Free Cash Flow | -$30.1M | -$23.4M | -28.66% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Personalis, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“These results reflect the strength of our team’s execution and commitment to helping transform the active management of cancer through more informed care,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X ( Twitter ).
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Personalis, Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.